Synapse

← JHEP Reports

Papers in JHEP Reports

Page 2 · newest first

  1. Integrative multi-omics identifies cholangiolocarcinoma as a distinct molecular subtype of intrahepatic cholangiocarcinomaJHEP Reports · 2026
  2. Machine Learning–Guided Personalized Immunochemotherapy Strategies in Intrahepatic CholangiocarcinomaJHEP Reports · 2026
  3. Integrative multi-omics analysis identifies stellate cell-derived complement component 7 as a predictor of fibrosis and liver-related events in MASLDJHEP Reports · 2026
  4. Corrigendum to: “HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers” [JHEP Reports 5 (2023) 100842]JHEP Reports · 2026
  5. Everolimus and de novo malignancies after liver transplantation: A nationwide emulated trial using real-world dataJHEP Reports · 2026
  6. Mapping of class II HLA restriction of SepSecS-specific CD4 T-cell epitopes in autoimmune hepatitisJHEP Reports · 2026
  7. Changes in alcohol use following a diagnosis of alcohol-related liver disease: A clinical cohort studyJHEP Reports · 2026
  8. Corticosteroids in severe alcohol-related hepatitis: a multicenter randomized clinical trialJHEP Reports · 2026
  9. A Pilot Study of Plasma Cell-Free DNA Fragmentomics in Gallbladder CancerJHEP Reports · 2026
  10. Delphi survey to explore core curriculum for training the next-generation of hepatologists☆JHEP Reports · 2026
  11. FGFR2 fusion-driven cholangiocarcinoma is characterized by a distinct neutrophil-enriched tumor microenvironment in a syngeneic murine modelJHEP Reports · 2026
  12. cfDNA derived gene signatures as surrogate for microvascular invasion in HCCJHEP Reports · 2026
  13. A risk-based post ablation follow-up strategy for hepatocellular carcinomaJHEP Reports · 2026
  14. Adjuvant capecitabine in resected biliary tract cancer: a real-world data from the BILCAP-Real study (ACABi multicentre cohort)JHEP Reports · 2026
  15. Shear Wave Elastography Combined with ALBI Score Enhances Prediction of Hepatic Decompensation in Chronic Liver DiseaseJHEP Reports · 2026
  16. Cholecystectomy before diagnosis of primary sclerosing cholangitis is associated with markedly worsened transplant free survivalJHEP Reports · 2026
  17. Post-transplant alloimmune liver disease in bile salt export pump deficiency: A multicenter studyJHEP Reports · 2026
  18. Fate of hepatitis D virus-specific CD8+ T cells during bulevirtide monotherapy in patients with chronic hepatitis delta☆JHEP Reports · 2026
  19. The Use of FGF21 Analogues in MASH and MASH Cirrhosis – Metabolic Master Regulators or Liver-Specific Mechanisms? ☆JHEP Reports · 2026
  20. Sexual dimorphism in the association of circulating TAM receptors–ligands with MASLD-related fibrosisJHEP Reports · 2026
  21. Perineural invasion in intrahepatic cholangiocarcinoma: Meta-analysis of prevalence, association with tumor features, and impact on survivalJHEP Reports · 2026
  22. Alcohol intake reprograms hepatic immune-metabolic circuits to exacerbate murine atherosclerosis and human cardiovascular riskJHEP Reports · 2026
  23. Reply to: “External validation of a simple risk stratification for portal hypertension-related clinical deterioration in patients with ascites”JHEP Reports · 2026
  24. Refined liver MRI-derived cT1 thresholds capturing hepatic fat fraction enhance mortality risk predictionJHEP Reports · 2026
  25. Functional Liver Imaging Score (FLIS): A Prognostic Biomarker for Acute-on-Chronic Liver Failure and Liver-Related MortalityJHEP Reports · 2026
  26. Interleukin-8–Driven Monocyte Activation in Primary Sclerosing Cholangitis: Insights from Single-Cell Analysis and Humanized Immune System MiceJHEP Reports · 2026
  27. Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinomaJHEP Reports · 2026
  28. Second-Line Practices in the Era of Immunotherapy in HCC: The CHIEF CohortJHEP Reports · 2026
  29. Alpha 2A adrenergic receptor antagonism reduces fibrosis, inflammation and portal hypertension in models of chronic liver diseaseJHEP Reports · 2026
  30. Bepirovirsen induces innate immune activation in the liver potentially through TLR8 signalingJHEP Reports · 2026
  31. Bezafibrate for primary biliary cholangitis: A number needed to treat analysisJHEP Reports · 2026
  32. lnc122 RNA prevents liver tumorigenesis in MYC-driven liver cancerJHEP Reports · 2026
  33. The purinergic receptor P2X4R stimulates macro-autophagy with impact on lipid droplet size in fatty liverJHEP Reports · 2026
  34. PNPLA3 polymorphisms and risk of hepatic and extrahepatic outcomes in MASLD: a meta-analysis of observational studiesJHEP Reports · 2026
  35. Assessing alcohol consumption in an era of direct alcohol markersJHEP Reports · 2026
  36. Pregnancy Outcomes in an International Cohort of Autoimmune HepatitisJHEP Reports · 2026
  37. Hepatitis C Virus Can Induce Gene Expression Changes Associated with HepatocarcinogenesisJHEP Reports · 2026
  38. LiRNA: An Interactive Atlas of Human Liver RNAseq DatabasesJHEP Reports · 2026
  39. Impact of weight loss and reduction of ultra-processed foods on liver fat content in MASLD: a randomized controlled trial.JHEP Reports · 2026
  40. Increasing incidence and changing trends in etiology & survival rates in HCC in a European cohortJHEP Reports · 2026
  41. Longitudinal GGT Trajectories Identify Prognostic Phenotypes in Paediatric Primary Sclerosing CholangitisJHEP Reports · 2026
  42. Long-term antigen reduction does not achieve durable HBV control in mice but enhances therapeutic vaccine efficacyJHEP Reports · 2026
  43. ANTICIPATE-ing a future without liver biopsy in MASH. Ready for prime time?JHEP Reports · 2026
  44. Genetic Testing in Liver Diseases: Clinical ApplicationsJHEP Reports · 2026
  45. Prognostic Significance of Pretreatment 18F-FDG PET/CT in Hepatocellular Carcinoma: A Systematic Review and Meta-AnalysisJHEP Reports · 2026
  46. Combining MRI criterion and pathology-based microvascular invasion improves prognostic stratification in early HCCJHEP Reports · 2026
  47. Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: insights from a multicenter European cohort.JHEP Reports · 2026
  48. Quantitative magnetic resonance cholangiopancreatography metrics improve prognostication in primary sclerosing cholangitisJHEP Reports · 2026
  49. Second-Line TKI after First-Line Immunotherapy-based Treatment in Advanced HCC: Reconstructed IPD Meta-analysisJHEP Reports · 2026
  50. Comment on: Real-world quality of life and healthcare resource utilization in patients with metabolic dysfunction-associated steatohepatitis – Circular definition of CVRM comorbidities undermines the validity of core subgroup comparisonsJHEP Reports · 2026